Costs and Cost Effectiveness of Alternatives for Cervical Cancer Screening and Treatment
Cervical cancer is one of the most common cancers among women worldwide. Most is caused by persistent infection with high-risk human papillomavirus (HPV). Recent research shows that HIV is a major risk factor for both HPV infection and progression to cervical cancer. In South Africa, where HIV prevalence is high, HPV infection and cervical cancer are significant public health challenges. Scarcity of service delivery capacity in rural communities and specialist services in urban communities limit access to cervical cancer screening and treatment. New models of service delivery and integration with existing HIV services are needed to expand access to these services. HE2RO’s work in this area includes conducting costing and cost effectiveness analyses comparing alternative approaches for screening, including sample collection, and treatment in traditional clinic-based and alternative settings such as mobile services.
Publications
The following publications emanate from this project:
-
Costs and cost-effectiveness of LEEP versus cryotherapy for treating cervical dysplasia among HIV-positive women in Johannesburg, South Africa
-
Cost-Effectiveness of Cervical Cancer Screening in Women Living With HIV in South Africa: A Mathematical Modeling Study
-
Costs and cost-effectiveness of LEEP versus cryotherapy for treating cervical dysplasia among HIV-positive women in Johannesburg, South Africa
-
Cost evaluation of reproductive and primary health care mobile service delivery for women in two rural districts in South Africa
-
The Costs of Cervical Cancer Screening and Treatment in Low and Middle Income Countries: A Systematic Review
-
Validation of Cervical Cancer Screening Methods in HIV Positive Women from Johannesburg South Africa
HE2RO staff involved
Naomi Lince-DerocheStay up to date
Receive newsletters and keep up to date with developments at HE2RO.